HIGHLIGHTS
- who: December et al. from the National Institute of Health (ISS), Italy University of Florida, United States have published the research work: Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling, in the Journal: (JOURNAL)
- what: In this in silico study, the authors aimed to investigate the DDI magnitude between daily oral rilpivirine 25 mg with either daily 600 mg or weekly 900 mg rifapentine.
- how: The PBPK model was designed in Simbiology (Matlab version 2018a). The following assumptions were made 1) well-stirred compartments with instant distribution of the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.